Differential effects of fedotozine compared to other κ agonists on diuresis in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 3, 1996, Pages 1379-1385

  Soulard, C D ^a   Guerif, S ^a   Payne, A ^a   Dahl, S G ^a  

^a Institut de Recherche Jouveinal   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; BREMAZOCINE; CYCLAZOCINE; DYNORPHIN A DERIVATIVE; ENADOLINE; FEDOTOZINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MORPHINE; MU OPIATE RECEPTOR; N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZO[B]THIOPHENE 4 ACETAMIDE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALOXONE; POTASSIUM ION; RECEPTOR SUBTYPE; SODIUM ION; TIFLUADOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DIURESIS; DOSE RESPONSE; DRUG INHIBITION; ELECTROLYTE EXCRETION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LATERAL BRAIN VENTRICLE; MALE; NONHUMAN; POTASSIUM EXCRETION; PRIORITY JOURNAL; RAT; SODIUM EXCRETION; SUBCUTANEOUS DRUG ADMINISTRATION; URINE VOLUME;

ANIMALS; BENZYL COMPOUNDS; DIURESIS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; PROPYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 0030434799     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. ABRAHAMS, J. M., BOURA, A. L. A., EVANS, R. G., JOHNSTON, C. I. AND OLLEY, J. E.: The effects of N-(cyclopropylmethyl)-19-isopentyl-nororvinol (M320), a potent agonist at κ- and μ- opiate receptors, on urine excretion of rats. Br. J. Pharmacol. 89: 759-767, 1986.
2. ALLESCHER, H. D., AHMAD, S., CLASSEN, M. AND DANIEL, E. E.: Interaction of trimebutine and JO 1196 (fedotozine) with opioid receptors in the canine ileum. J. Pharmacol. Exp. Ther. 267: 836-842, 1991.
3. ASHTON, N., BALMENT, R. J. AND BLACKBURN, T. P.: κ-Opioid-induced changes in renal water and electrolyte management and endocrine secretion. Br. J. Pharmacol. 97: 769-776, 1989.
4. ASHTON, N., BALMENT, R. J. AND BLACKBURN, T. P.: κ-Opioid-receptor agonists modulate the renal excretion of water and electrolytes in anaesthetized rats. Br. J. Pharmacol. 99: 181-185, 1990.
5. BLACKBURN, T. P., BORKOWSKI, K. R., FRIEND, J. AND RANCE, M. J.: On the mechanisms of κ-opioid-induced diuresis. Br. J. Pharmacol. 89: 593-598, 1986.
6. BROOKS, D. P., GIARDINA, G., GELLAI, M., DONDIO, G., EDWARDS, R. M., PETRONE, G., DEPALMA, P. D., SBACCHI, M., JUGUS, M., MISIANO, P., WANG, Y.-X. AND CLARKE, G. D.: Opiate receptors within the blood-brain barrier mediate kappa agonist-induced water diuresis. J. Pharmacol. Exp. Ther. 266: 164-171, 1993.
7. 3 subtype. J. Pharmacol. Exp. Ther. 251: 461-468, 1989.
8. COLOMBO, M., PETRILLO, P., REGINA, L. A., BIANCHI, G. AND TAVANI, A.: in vitro binding profile and in vivo pharmacological properties of the K-opioid compound PD 117302. Res. Com. Chem. Path. Pharmacol. 72: 295-306, 1991.
9. COWAN, A. AND KHUNAWAT, P.: Increased urine output by rats after intracerebroventricular administration of kappa agonists. Ann. N.Y. Acad. Sci. 463: 174-176, 1986.
10. GAVEND, M., GAVEND, M.-R. AND SERRE, F.: Etude expérimentale de l'action diurétique d'un antagoniste des morphiniques, la cyclazocine. J. Pharmacol. (Paris) 9: 77-88, 1978.
11. GAVEND, M., MALLARET, M., CARON, F. AND BARAGATTI, G.: Antagonism of metergoline on the diuretic effect of cyclazocine and U-50,488 drugs with a kappa agonist activity. Biomed. Pharmacother. 47: 337-344, 1993.
12. GUTKOWSKA, J., RACZ, K., GARCIA, R., THIBAULT, G., KUCHEL, O., GENEST, J. AND CANTIN, M.: The morphine effect on plasma ANF. Eur. J. Pharmacol. 131: 91-94, 1986.
13. GUTKOWSKA, J., STRICK, D. M., PAN, L. AND McCANN, S. M.: Effect of morphine on urine output: Possible role of atrial natriuretic factor. Eur. J. Pharmacol. 242: 7-13, 1993.
14. HAAF, J. A. T., MAIGRET, C., ANDRINGA-BAKKER, E. A. D. AND VAN WIMERSMA GREIDANUS, T. B.: Dynorphin-(1-13) is a potent in vivo suppressor of vasopressin levels in the rat. Acta Endocrinol. 114: 96-101, 1987.
15. HAMON, G. AND JOUQUEY, S.: Kappa agonists and vasopressin secretion. Horm. Res. 34: 129-132, 1990.
16. HAYES, A. G., SKINGLE, M. AND TYERS, M. B.: Evaluation of the receptor selectivities of opioid drugs by investigating the block of their effect on urine output by β-funaltrexamine. J. Pharmacol. Exp. Ther. 240: 984-988, 1987.
17. HUIDOBRO, F.: Antidiuretic effect of morphine in rats. Tolerance and physical dependence. Br. J. Pharmacol. 64: 167-171, 1978.
18. HUIDOBRO, F. AND HUIDOBRO-TORO, J. P.: Antidiuretic effect of morphine and vasopressin in morphine tolerant and non-tolerant rats, differential effects on urine composition. Eur. J. Pharmacol. 59: 55-64, 1979.
19. 2 met-enkephalinamide on urine production and urinary electrolytes in the rat. Life Sci. 24: 697-705, 1979.
20. HUIDOBRO-TORO, J. P. AND PARADA, S.: Pharmacological evidences for an endogenous role of kappa-opiate receptor in fluid and electrolyte balance. Eur. J. Pharmacol. 107: 1-9, 1984.
21. HUNTER, J. C., LEIGHTON, G. E., MEECHAM, K. G., BOYLE, S. J., HORWELL, D. C., REES, D. C. AND HUGHES, J.: CI-977, a novel and selective agonist for the κ-opioid receptor. Br. J. Pharmacol. 101: 183-189, 1990.
22. KAPUSTA, D. R., JONES, S. Y. AND DIBONA, G. F.: Role of renal nerves in excretory responses to administration of kappa agonists in conscious spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 251: 230-237, 1989.
23. KAPUSIA, D. R. AND OBIH, J. C.: Central kappa opioid receptor-evoked changes in renal function in conscious rats: Participation of renal nerves. J. Pharmacol. Exp. Ther. 267: 197-204, 1993.
24. LAURENT, S. AND SCHMITT, H.: Central cardiovascular effects of κ agonists dynorphin-(1-13) and ethylketocyclazocine in the anaesthetized rat. Eur. J. Pharmacol. 96: 165-169, 1983.
25. LEANDER, J. D.: A kappa opioid effect: Increased urination in the rat. J. Pharmacol. Exp. Ther. 224: 89-94, 1983a.
26. LEANDER, J. D.: Further study of kappa opioids on increased urination.: J. Pharmacol. Exp. Ther. 227: 35-41, 1983b.
27. LEANDER, J. D.: κ-opioid diuretic effects of tifluadom, a benzodiazepine opioid agonist. J. Pharm. Pharmacol. 38: 555-556, 1984a.
28. LEANDER, J. D.: Effects of full and partial kappa agonists and mu agonists on urine output of normally hydrated rats, Neuropeptides 5: 283-286, 1984b.
29. LEANDER, J. D.: Delineation of mu-antagonist, partial kappa agonist and non-opioid agonist activity of cyclazocine using urinary output of rats. Pharmacol. Biochem. Behav. 26: 705-707, 1987a.
30. LEANDER, J. D.: Bremazocine-induced urination in rats of different sizes. Res. Com. Chem. Path. Pharmacol. 57: 141-144, 1987b.
31. LEANDER, J. D., HART, J. C. AND ZERBE, R. L.: Kappa agonist-induced diuresis: Evidence for stereoselectivity, strain differences, independence of hydration variables and a result of decreased plasma vasopressin levels. J. Pharmacol. Exp. Ther. 242: 33-39, 1987.
32. MARCHAND, C.: The diuretic and antidiuretic effect of morphine sulfate in rats. Proc. Soc. Exp. Biol. Med., 133: 1303-1306, 1970.
33. 3 H]ethylketocyclazocine. Life Sci. 42: 2403-2412, 1988.
34. 14C]serotonin in rat brain. J. Neurochem. 14: 63-69, 1967.
35. PASOAUD, X., HONDE, C., L. E. GALLOU, B., CHANOINE, F., ROMAN, F., BUENO, L. AND JUNIEN, J. L.: Effects of fedotozine on gastrointestinal motility in dogs: mechanism of action and related pharmacokinetics. J. Pharm. Pharmacol. 42: 546-552, 1990.
36. PESONEN, A., LEPPALUOTO J. AND RUSKOAHO H.: Mechanism of opioid-induced atrial natriuretic peptide release in conscious rats. J. Pharmacol. Exp. Ther. 254: 690-695, 1990.
37. PETERS, G. R., WARD, N. J., ANTAL, E. G., LAI, P. Y. AND DEMAAR, E. W.: Diuretic actions in man of a selective kappa opioid agonist: U-62.066E. J. Pharmacol. Exp. Ther. 240: 128-131, 1987.
38. RATHBUN, R. C., KATTAU, R. W. AND LEANDER, J. D.: Effects of mu- and kappa-opioid receptor agonists on urinary output in mice. Pharmacol. Biochem. Behav. 19: 863-866, 1983.
39. RIMOY, G. H., BHASKAR, N. K., WRIGHT, D. M. AND RUBIN, P. C.: Mechanism of diuretic action of spiradoline (U-62066E) a kappa opioid receptor agonist in the human. Br. J. Clin. Pharmacol. 32: 611-615, 1991.
40. RIVIERE, P. J. M., PASCAUD, X., CHEVALIER, E., LE GALLOU, B. AND JUNIEN, J. L.: Fedotozine reverses ileus induced by surgery or peritonitis: Action at peripheral κ-opioid receptors. Gastroenterology 104: 724-731, 1993.
41. 8]-dynorphin-A-(1-8)ethylamide, a stable dynorphin analog, produces diuresis by kappa-opiate receptor activation in the rat. J. Pharmacol. Exp. Ther, 262: 979-986, 1992.
42. SALAS, S. P., ROBLERO, J. S., URETA, N. AND HUIDOBRO-TORO, J. P.: Diuretic effect of bremazocine, a kappa-opioid with central and peripheral sites of action. J. Pharmacol. Exp. Ther. 250: 992-999, 1989.
43. SLIZGI, G. R. AND LUDENS, J. H.: Studies on the nature and mechanism of the diuretic activity of the opioid analgesic ethylketocyclazocine. J. Pharmacol. Exp. Ther. 220: 585-591, 1982.
44. TAKEMORI, A. E., SCHWARTZ, M. M. AND PORTOGHESE, P. S.: Suppression by nor-binaltorphimine of kappa opioid-mediated diuresis in rats. J. Pharmacol. Exp. Ther. 247: 971-974, 1988.
45. TSENG, L. F., WEI, E. T., LOH, H. N. AND LI, C. H.: β-Endorphin: Antidiuretic effects in rats. Int J. Peptides Res. 12: 173-178, 1978.
46. TSUSHIMA, H., MORI, M. AND MATSUDA, T.: Microinjection of dynorphin into the supraoptic and paraventricular nuclei produces antidiuretic effects through vasopressin release. Japan. J. Pharmacol. 63: 461-468, 1993.
47. URANO, A. AND KOBAYASHI, H.: Effects of noradrenaline and dopamine injected into the supraoptic nucleus on urine flow rate in hydrated rats. Exp. Neurol. 60: 140-150, 1978.
48. URETA, H., LOPEZ, L. F., PEREZ, A. AND HUIDOBRO-TORO, J. P.: κ-Opiate-induced diuresis and changes in blood pressure: Demonstration of receptor stereoselectivity using(+)- and (-)-tifluadom. Eur. J. Pharmacol. 135: 289-295, 1987.
49. VAUPEL, D. B., CONE, E. J., JOHNSON, R. E. AND SU, T.-P.: Kappa opioid partial agonist activity of the enkephalin-like pentapeptide BW942C based on urination and in vitro studies in humans and animals. J. Pharmacol. Exp. Ther. 252: 225-234, 1990.
50. VOLLMAR, A. M., ARENDT, R. M. AND SCHULZ, R.: The effect of opioids on rat plasma atrial natriuretic peptide. Eur. J. Pharmacol. 143: 315-321, 1987.
51. VON VOIGTLANDER, P. F., LAHTI, R. A. AND LUDENS, J. H.: U-50488H: A selective and structurally novel non-mu (kappa) opioid agonist. J. Pharmacol. Exp. Ther. 224: 7-12, 1983.
52. 2 (DAFPHEDYN): A potent analog of dynorphin 1-13. Peptides 8: 811-817, 1987.
53. WALKER, L. A. AND MURPHY, J. C.: Antinatriuretic effect of acute morphine administration in conscious rats. J. Pharmacol. Exp. Ther. 229: 404-408, 1984.
54. YOUNG, E. A., WALKER, J. M., HOUGHTEN, R. AND AKIL, H.: The degradation of dynorphin A in brain tissue in vivo and in vitro. Peptides 8: 701-707, 1987.
55. 2 opioid receptors. Proc. Natl. Acad. Sci. U.S.A. 85: 4061-4065, 1988.